Glaucoma is the leading cause of irreversible blindness worldwide and is a particular burden on the Asian population. Glaucoma surgeries such as trabeculectomy and glaucoma drainage implants are routinely performed to lower intraocular pressure (IOP) to prevent disease progression. However, scarring of the filtering bleb limits their long-term success and Asian eyes are more at risk. Although this is so, many existing studies have been done on Caucasian patients, but few have focused solely on Asian patients. Intraoperative anti-metabolites such as Mitomycin-C (MMC) and 5-Fluorouracil (5-FU) are the current mainstay of adjunctive treatments to reduce scarring, and in this review, we evaluate the evolution, benefits and side effects of these agents. Recently, newer methods of wound modulation including anti-vascular endothelial growth factor (VEGF) agents and collagen implants are also being investigated as part of a multi-pronged approach to tackle this problem. Some opportunities exist to limit scarring post-operatively, but it is an ongoing battle.
INTRODUCTION
Glaucoma is a specific optic neuropathy with characteristic optic disc changes and visual fields defects, in which elevated intraocular pressure (IOP) is one of the primary risk factors. It is one of the leading causes of blindness worldwide 1, 2 . With the rapidly aging population, the number of patients with open angle glaucoma and angle closure glaucoma worldwide is estimated to increase from 60.5 million people in 2010, to 79.6 million people in 2020 2 . More than 50% of the glaucoma patients are Asians, and the vast majority of the world's angle closure glaucoma patients are Asians 1 . Hence, this represents a significant public health problem in this part of the world. The prevalence of glaucoma among Singaporeans 40 years of age and older is about 3.2%, 3.4% and 1.95% in the Chinese, Malay and Indian populations respectively [3] [4] [5] .
The goal of glaucoma therapy is to prevent disease progression and further visual loss. To date, lowering the IOP is the only proven modifiable risk factor [6] [7] [8] .
The IOP can be lowered by ocular hypotensive medications, laser treatment, or surgical treatment. Surgery is required in a considerable number of glaucoma patients to adequately control the IOP.
Conjunctival and scleral scarring after surgery remains a major limiting factor to the success of glaucoma surgery, especially so in Asian eyes which have a higher risk of scarring compared to Caucasian eyes. Over the past few decades, there has been an increasing use of various anti-fibrotic agents to modulate the wound healing response. In this article, we will discuss the outcomes of glaucoma surgeries in Asian eyes, and review the various wound healing modulation techniques in glaucoma surgery.
GLAUCOMA SURGICAL PROCEDURES Glaucoma Filtration Surgery
Glaucoma filtration surgery (GFS) or trabeculectomy ( Fig. 1) is the creation of a guarded fistula for the flow of aqueous from the anterior chamber of the eye, through the sclerostomy, into the subconjunctival Review Proceedings of Singapore Healthcare  Volume 24  Number 2  2015 space 9 . Despite several emerging new glaucoma surgical techniques, trabeculectomy is still the current reference standard. A marker of surgical success is the formation of a functioning filtering bleb and a persistently low IOP, indicating fluid has drained into the subconjunctival space.
Glaucoma Drainage Devices
Glaucoma drainage devices (GDD) or aqueous shunts ( Fig. 2 ), work similarly but by placing a tube into the eye to drain fluid into the subconjunctival space via a plate secured to the sclera. They can be divided into non-valved, or valved devices. Examples of the non-valved devices are the Baerveldt (Advanced Medical Optics, Inc, Santa Ana, CA) and Molteno (Molteno Ophthalmic Ltd, Dunedin, New Zealand), and an example of the valved device is the Ahmed (New World Medical, Inc, Rancho Cucamonga, CA). These devices are generally reserved for refractory glaucoma cases in which filtration surgery has failed or is likely to fail. Aqueous humour flows through the tube to an extraocular reservoir around the explant 9 . A fibrovascular encapsulation forms around the plate, and IOP lowering is dependent on the resistance of aqueous flow across the fibrovascular capsule; a thinner capsule is associated with lower IOP.
PATHOGENESIS OF SCARRING IN GLAUCOMA SURGERY
Remodelling and scar formation is the third and final phase of the normal wound healing process in GFS 10 . The first two phases consist of (i) immediate inflammatory response, as well as (ii) proliferation and tissue reparation. Immediate inflammatory response occurs in the early postoperative days, where cytokines and growth factors are released. These trigger the second phase. Proliferation and tissue reparation then occurs, which comprises of activation, migration and proliferation of episcleral fibroblasts, formation of vascular tufts and collagen bundles. Finally, the third phase will include the contraction of collagen fibers synthesised by the activated fibroblasts, leading to the formation of scar tissue which reduces aqueous humour drainage and subconjunctival absorption.
SCARRING AND SURGICAL OUTCOMES IN ASIANS
Asian skin is different from Caucasian skin. Asians have a thicker dermis, with a more vigorous fibroblastic response during wound healing, and a tendency to form hyperpigmentation and scarring following skin injury 11 . Keloids, which are fibroproliferative scars that extend beyond the border of the original wound, are also ten times more prevalent in Asians compared to Caucasians 12 . Since the skin and the conjunctiva share similar healing mechanisms, an exaggerated wound healing process in the ocular a b tissues is expected in Asians. While the conjunctival cell profile of Asians has not been studied, histological differences have been found between that of African and Caucasian patients, with the conjunctiva of African patients containing a greater number of fibroblasts and macrophages 13 . This explains the lower surgical success rates seen following GFS in Africans.
Unaugmented trabeculectomy outcomes have been reported to be poorer in Asian eyes compared to Caucasian eyes 14- 16 . In two Singapore series, the overall success rate of unaugmented trabeculectomy was only 43.1% at 2 years 14 , and 36.4% at 3 years 15 . This contrasts with a series of 150 Caucasian eyes, with 90% of the eyes achieving adequate IOP control following unaugmented trabeculectomy after 110 months of follow-up 17 .
Interestingly, the success rates of GDDs in Asian eyes do not differ from non-Asian eyes [18] [19] [20] [21] [22] and are generally good at 67-94% of post intervention success 18 
METHODS OF WOUND MODULATION Anti-inflammatory agents
The hallmark prospective trial by Starita et al. 23 proved the benefits of topical steroids after trabeculectomy.
The study showed an improved outcome in the topical steroids group, whereas systemic steroids did not provide any additional benefits. The beneficial effects continue to be seen in the 10-year follow-up study, with stabilisation of glaucoma in 82.7% of the steroid-treated eyes and 67% in the non-steroid treated eyes 24 . In clinical practice, there is wide variation with regards to the topical steroid dosage and treatment duration, which is tailored to the target IOP and the morphological features of the bleb itself.
Antimetabolites
The use of antimetabolites such as 5-Fluorouracil (5-FU) and Mitomycin C (MMC) in conjunction with glaucoma surgery is now established clinical practice. The properties of 5-FU and MMC are indicated in Table 1 .
5-Fluorouracil (5-FU) Glaucoma Filtration Surgery
The landmark multicentre Fluorouracil Filtering Surgery Study demonstrated higher success rates in trabeculectomies in high-risk eyes that received post-operative subconjunctival 5-FU injections 25 . These eyes had lower IOP, longer bleb survival, and a decreased need for repeat surgeries: ben-
5-Fluorouracil Mitomycin C

Mechanism of action
A fluorated pyrimidine analogue that inhibits thymine nucleotide synthesis and DNA synthesis. It inhibits fibroblast proliferation in human Tenon's capsule, and effect is reversible after 1 week
An antibiotic with antiproliferative properties that cross-links DNA and inhibits DNA synthesis. It reduces fibroblast numbers and inhibits endothelial cell growth in human Tenon's capsule with prolonged effects for at least 30 days
Phase of cell cycle affected
It acts selectively on the synthesis phase of the cell cycle
It affects all phase of the cell cycle, and can inhibit DNA replication, mitosis, and protein synthesis
Clinical application
Intraoperative or post-operative subconjunctival injection Intraoperative subconjunctival application of MMC
Complications related to anti-metabolite
It is associated with an increased risk of wound leak, shallow anterior chamber, hypotonus maculopathy, and corneal epithelial damage 24 It is associated with thin-walled, avascular, cystic blebs, as well as bleb leaks, hypotonus maculopathy, endophthalmitis, and cataract progression 25,26 The 2014 Cochrane update on the use of 5-FU for glaucoma surgery reviewed 12 randomised trials, and concluded that there is a small but statistically significant reduction in surgical failures and IOP at one year for trabeculectomies augmented with 5-FU, especially so in high-risk eyes, without evidence of serious sight-threatening complications 28 . The trial participants were mainly Caucasian patients.
To date, there have only been a few long-term studies on the outcome of 5-FU-augmented trabeculectomy in Asian patients. The Singapore 5-FU trial was a randomised controlled trial involving 243 Asian patients with primary glaucoma who either received intra-operative 5-FU (50mg/ml) or placebo during trabeculectomy. At 3 years, a significantly lower failure rate of 58.2% was reported in the 5-FU group compared to 73.7% in the placebo group, with failure criterion of IOP >17 mmHg 29 . There was also a trend towards lower IOP medication use in the 5-FU group, although this did not reach statistical significance (23% versus 34%, p=0.06). However at 8 years, there was no significant difference in the IOP between the 5-FU and placebo groups 30 .
In a study of 117 Japanese patients with POAG, Uchida et al. found that trabeculectomy with subconjunctival 5-FU was effective. The patients received an intra-operative injection of 0.1 ml 5% 5-FU, followed by daily subconjunctival injections of 5-FU for one week, and every other day for the second week. They reported a complete success rate of 57.6% at 6 years, and 50.4% at 12 years achieving an IOP <21 mmHg 31 .
Glaucoma Drainage Devices (GDD)
The outcomes on the use of 5-FU with GDD has been mixed. Alvarado et al. reported favourable outcomes following Ahmed implant with the combined use of intra-operative MMC and postoperative 5-FU, with a high long-term success rate, an obtunded hypertensive phase, and a low rate of complications 32 . However, this study is flawed by the lack of a comparative group, and it is difficult to discriminate whether it was the 5-FU or MMC or both that contributed to the success rate. In a comparative series in eyes with Baerveldt implant, Tribe et al did not find any influence of 5-FU nor MMC on the early post-operative IOP 33 . There are no studies on the use of 5-FU with GDD in Asian eyes to date.
Mitomycin-C (MMC) Glaucoma Filtration Surgery(GFS)
Mitomycin-C is 100 times more potent than 5-FU, and its prolonged anti-fibrotic effects makes it suitable as a single-use adjunct in GFS. The Cochrane review on the intraoperative use of MMC with trabeculectomy versus placebo assessed 11 trials, concluded that intraoperative MMC reduces the risk of surgical failure in eyes without previous surgery (relative risk of 0.32) and in high-risk eyes (relative risk of 0.29) at 12 months 34 . Compared to placebo, MMC lowers IOP by 5.41 mmHg more than placebo in eyes without previous surgery, and by 5.31 mmHg more than placebo in high-risk eyes.
In a meta-analysis of five randomised controlled clinical trials by De Fendi et al., the use of MMC was associated with a significantly lower post-operative mean IOP and significantly higher rates of complete and qualified surgical success compared with the use of 5-FU with a mean follow-up of 10 months 35 .
For success taken as IOP ≤21 mmHg at 12 months with the use of medications, the complete surgical success rate was 75.7% in the MMC group and 62% in the 5-FU groups (P=0.03). For success taken as IOP ≤18 mmHg, the qualified surgical success was again higher in the MMC group than the 5-FU group (83.3% versus 75%, P=0.04).
Long-term results of MMC use have been acceptable [36] [37] [38] [39] . A large case series of 123 eyes studied the use of MMC in trabeculectomy, and reported a significant decrease in the IOP at 5 years post-operation (pre-operative IOP of 25.79 mmHg versus 5-year post-operative IOP of 9.91 mmHg) 36 . Another large case-controlled study of 203 eyes with POAG that underwent glaucoma and cataract surgery procedure with and without adjunctive MMC, demonstrated better IOP control and stable visual fields in the MMC group compared to the control group at 36 months after surgery 37 . Other series report a success rate (IOP ≤18 mmHg) of 85-87% at 1 year, 67% at 2 years, and 62% at 3 years post-operatively 38 A long-term series of 123 eyes of Japanese patients showed a success rate of 71.3% and 67% at 5 and 8 years post-operatively (IOP <18 mmHg) 42 .
In terms of the method of administration, the use of intra-operative MMC injection has proven to be as safe and as effective as conventional spongeapplied MMC, with less need for post-operative 5-FU interventions. A recent retrospective study which compared the two methods performed on 50 eyes 43 showed that the proportion of eyes achieving IOP reduction >30% from baseline were similar with no significant difference between the two groups in post-op complications. Similar outcomes were reported in another larger retrospective study 44 , where MMC was applied by injection in 125 eyes and by sponge in 57 eyes. Both groups had a similar reduction in IOP from baseline, with a mean IOP of around 12 mmHg 3 years after surgery. Postoperatively, eyes in the sponge group were more likely to receive 5-FU injections and were at higher risk of developing a tense or vascularised bleb. The advantages of MMC injection are that they save time as there is no need to apply the sponges for a few minutes any more and the possibility of getting retained fragments of sponges is circumvented.
Glaucoma Drainage Devices (GDD)
The findings on the use of MMC with GDD have been mixed. As discussed earlier, Alvarado et al. reported a high success rate in Ahmed implant with the combined use of intra-operative MMC and post-operative 5-FU 33 . Other studies, including two randomised controlled trials, found no significant benefits with the use of MMC in various GDD [45] [46] [47] [48] .
There are no studies on the use of MMC with GDD in Asian eyes to date.
Needling with 5-FU and MMC
Fibrosis after trabeculectomy is common, especially in Asians, leading to a failing or failed bleb. Revision procedures can be done for the bleb in the form of needling where needle incisions are used to perforate a fibrosed bleb, thus re-establishing aqueous flow and achieving normal IOP 49 . Agents such as 5-FU and MMC can be injected sub or trans-conjunctivally to increase the success rate of needling. One recent study comparing MMC with 5-FU concluded that MMC was more effective in restoring failed filtering blebs than 5-FU 50 ). The 5-FU group had significantly longer mean follow-ups of 53 months compared with 33 months in the MMC group, as well as a significantly higher number of needle revisions than MMC group (1.9 vs. 1.2).
NEWER METHODS OF WOUND MODULATION Anti-VEGF
Vascular endothelial growth factor (VEGF) plays a major role in angiogenesis and the wound healing process. Ocular anti-VEGF therapy has been used in the treatment of various ophthalmic diseases including neovascular age-related macular degeneration and diabetic macular oedema. The two most commonly used anti-VEGF agents in the eye are ranibizumab and bevacizumab. Ranibizumab has been FDA approved for intraocular injection, whereas bevacizumab is used off-label for ocular conditions.
Following glaucoma surgery, VEGF is up-regulated in the Tenon's tissue, and stimulates fibroblast proliferation, contributing to scar formation 51 ). A higher VEGF level in Tenon's tissue at the time of surgery has been found to be significantly associated with surgical failure at 1 year 52 . Hence, the biologically plausible use of anti-VEGF agents as an adjunct to glaucoma surgery has been proposed.
Further studies highlighted a reduction in postoperative scarring and bleb failure with the use of sub-conjunctival bevacizumab either at the time of trabeculectomy, or with bleb needling [53] [54] [55] .
There are very few studies evaluating the use of anti-VEGF agents with GDD implantation. with neovascular glaucoma resulted in a significantly lower IOP at post-operative 12 and 15 months compared to the control group, even though the cumulative probabilities of surgical success was not significantly different between the two groups 58 . Table 2 shows a summary of the studies comparing the use of anti-VEGF agents with anti-metabolites in glaucoma surgery [59] [60] [61] [62] [63] [64] [65] [66] .
There is currently insufficient evidence to recommend the use of anti-VEGF over anti-metabolites as the sole adjunct to glaucoma surgery. The optimal route of administration and dosing regimen are still uncertain. Further studies are needed in this area. There are no studies on the use of anti-VEGF in glaucoma surgery in Asian eyes to date.
OTHER AGENTS AND TECHNIQUES Growth Factor Modulators
The aqueous flowing through the bleb contains a large number of growth factors, in particular, transforming growth factor beta (TGF-b). A recombinant human monoclonal antibody to TGF-b2, CAT-152 appears to inhibit TGF-b2 mediated conjunctival scarring in-vitro 67 . However, a phase III randomised trial of CAT-152 for primary trabeculectomy has yielded disappointing results, with no difference seen between CAT-152 and placebo in preventing surgical failure 68 .
Matrix Metalloprotease Inhibitors
Matrix metalloprotease (MMP) are key proteins involved in wound healing and have been shown to be up-regulated in bleb tissue. Currently MMP inhibitors are under investigation for use in glaucoma surgery. In a rabbit trabeculectomy model, postoperative injections of Ilomastat, a broad-spectrum MMP inhibitor, were shown to reduce scarring and prolong the bleb survival to the same extent as MMC, without histological toxicity 69 . Another rabbit trabeculectomy study showed similar IOP control and bleb appearance and inflammation between topical doxycycline and MMC 70 . Matrix metalloprotease inhibition may provide an additional method of wound modulation in glaucoma surgery.
Ologen Implant
Ologen is a biodegradable, porous, porcine collagen matrix that has been used as a subconjunctival spacer during trabeculectomy to modify the fibrosis process. It is believed to reduce subconjunctival scarring. A recent meta-analysis evaluating the use of ologen implant versus MMC in primary trabeculectomy found that Ologen implant was comparable to MMC in long-term surgical success and incidence of complications 71 . However, recent local studies from Singapore 72, 73 have shown that mean bleb height was lower in Ologen blebs compared with the MMC blebs, and the eyes with Ologen implants still require more frequent bleb needling procedures and these results do not correspond to the Cochrane review. Ologen implants also do not seem to offer significant advantages of avoiding the potential complications related to MMC.
Minimally Invasive Glaucoma Surgery (MIGS)
Minimally invasive glaucoma surgery is a collective term for procedures that are bleb-independent, including trabecular bypass stents and canaloplasty, which aim to avoid the major complications of fistulating surgery related to blebs and hypotony 74 . However, it has to be noted that MIGS has its own set of complications such as transient hyphaema, Descemet's detachment in canaloplasty and limited IOP improvements in some of the stent procedures. Little is known about the long-term success and the effects of scarring and how racial differences may affect success rates. As these techniques are bleb independent, traditional intraoperative antimetabolites cannot be used to limit scarring and failure. Similarly, adjunctive treatments analogous to needling are impossible once scarring sets in, however, these do not preclude moving on to traditional filtering procedures afterwards.
Novel Drug Delivery System
Several novel sustained-release delivery systems are being studied. A randomised controlled trial evaluating a novel formulation of 5-FU combined with hyaluronic acid as an adjunct to bleb needling has shown that it is more effective than 5-FU alone 75 . The combined formulation provides a sustained release of 5-FU and was associated with a lower frequency of repeat needling interventions. Biodegradable 5-FU plugs placed within Baerveldt tubes, and porous film coating with 5-FU and MMC within the Ahmed tubes, have the potential to increase the success rate of GDD 76, 77 .
CONCLUSION
Asian eyes exhibit a more intense healing response and are prone to scarring and surgical failure following GFS. However, to date there is still a lack of data reporting glaucoma surgery specifically in Asian patients, with even less information available on the use of anti-scarring medications Proceedings of Singapore Healthcare  Volume 24  Number 2  2015 in Asians. Even though the outcomes of GDD are not different between Asian and non-Asian eyes, increased surgical failure is seen with GDD over time. Wound healing modulation holds the key to the success of glaucoma surgery. Currently, the use of anti-inflammatory agents and anti-metabolites in conjunction with glaucoma surgery are well-established clinical practices. However, these agents are far from perfect. As we develop a better understanding of the associated biological processes in wound healing, the search for more targeted drugs and better drug delivery continues.
